163 related articles for article (PubMed ID: 12713251)
1. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome.
Obata K; Sakazume S; Yoshino A; Murakami N; Sakuta R
J Pediatr Endocrinol Metab; 2003 Feb; 16(2):155-62. PubMed ID: 12713251
[TBL] [Abstract][Full Text] [Related]
2. Effects of growth hormone treatment on height, weight, and obesity in Taiwanese patients with Prader-Willi syndrome.
Lin HY; Lin SP; Tsai LP; Chao MC; Chen MR; Chuang CK; Huang CY; Tsai FJ; Chou IC; Chiu PC; Huang CH; Yen JL; Lin JL; Kuo PL
J Chin Med Assoc; 2008 Jun; 71(6):305-9. PubMed ID: 18567561
[TBL] [Abstract][Full Text] [Related]
3. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
Fillion M; Deal C; Van Vliet G
J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
[TBL] [Abstract][Full Text] [Related]
5. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
[TBL] [Abstract][Full Text] [Related]
6. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
[TBL] [Abstract][Full Text] [Related]
7. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency.
Schmidt H; Bechtold S; Schwarz HP
Eur J Med Res; 2000 Jul; 5(7):307-10. PubMed ID: 10903191
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.
Angulo M; Castro-Magana M; Mazur B; Canas JA; Vitollo PM; Sarrantonio M
J Pediatr Endocrinol Metab; 1996; 9(3):393-400. PubMed ID: 8887149
[TBL] [Abstract][Full Text] [Related]
11. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
Scheermeyer E; Harris M; Hughes I; Crock PA; Ambler G; Verge CF; Bergman P; Werther G; Craig ME; Choong CS; Davies PSW;
Growth Horm IGF Res; 2017 Jun; 34():1-7. PubMed ID: 28427039
[TBL] [Abstract][Full Text] [Related]
12. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.
Lindgren AC; Ritzén EM
Acta Paediatr Suppl; 1999 Dec; 88(433):109-11. PubMed ID: 10626558
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
14. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment.
Angulo MA; Castro-Magana M; Lamerson M; Arguello R; Accacha S; Khan A
Am J Med Genet A; 2007 Jul; 143A(13):1456-61. PubMed ID: 17567883
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
[TBL] [Abstract][Full Text] [Related]
16. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome.
Dağdeviren Çakır A; Baş F; Akın O; Şıklar Z; Özcabı B; Berberoğlu M; Kardelen AD; Bayramoğlu E; Poyrazoğlu Ş; Aydın M; Törel Ergür A; Gökşen D; Bolu S; Aycan Z; Tüysüz B; Ercan O; Evliyaoğlu O
J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):308-319. PubMed ID: 33565750
[TBL] [Abstract][Full Text] [Related]
19. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome.
Hauffa BP
Acta Paediatr Suppl; 1997 Nov; 423():63-5. PubMed ID: 9440907
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
Acta Paediatr; 1998 Jan; 87(1):28-31. PubMed ID: 9510443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
